Which has stronger valuation & earnings, PFE or ONC?

Pfizer has higher revenue and earnings than BeOne Medicines. Pfizer is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.55 $7.77B $0.76 36.80 BeOne Medicines $5.34B 7.64 $286.93M $5.68 65.49

Is PFE or ONC more profitable?

BeOne Medicines has a net margin of 10.70% compared to Pfizer's net margin of 6.80%. Pfizer's return on equity of 19.63% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 6.80% 19.63% 8.46% BeOne Medicines 10.70% 14.23% 7.82%

Does the media refer more to PFE or ONC?

In the previous week, Pfizer had 92 more articles in the media than BeOne Medicines. MarketBeat recorded 94 mentions for Pfizer and 2 mentions for BeOne Medicines. Pfizer's average media sentiment score of 0.94 beat BeOne Medicines' score of 0.53 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 54 Very Positive mention(s) 12 Positive mention(s) 15 Neutral mention(s) 7 Negative mention(s) 5 Very Negative mention(s) Positive BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ONC or BMY?

In the previous week, Bristol Myers Squibb had 73 more articles in the media than BeOne Medicines. MarketBeat recorded 75 mentions for Bristol Myers Squibb and 2 mentions for BeOne Medicines. Bristol Myers Squibb's average media sentiment score of 1.53 beat BeOne Medicines' score of 0.53 indicating that Bristol Myers Squibb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bristol Myers Squibb 68 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, SNY or ONC?

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.24 $8.84B $1.91 23.92 BeOne Medicines $5.34B 7.64 $286.93M $5.68 65.49

Is SNY or ONC more profitable?

BeOne Medicines has a net margin of 10.70% compared to Sanofi's net margin of 8.66%. BeOne Medicines' return on equity of 14.23% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 8.66% 14.19% 7.95% BeOne Medicines 10.70% 14.23% 7.82%

Which has preferable earnings & valuation, ONC or GSK?

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 7.64 $286.93M $5.68 65.49 GSK $43.07B 2.43 $7.54B $3.20 16.19

Is ONC or GSK more profitable?

GSK has a net margin of 14.56% compared to BeOne Medicines' net margin of 10.70%. GSK's return on equity of 43.23% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 10.70% 14.23% 7.82% GSK 14.56% 43.23% 11.60%

Does the media favor ONC or GSK?

In the previous week, BeOne Medicines and BeOne Medicines both had 2 articles in the media. GSK's average media sentiment score of 0.55 beat BeOne Medicines' score of 0.53 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GSK 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ONC or TAK?

BeOne Medicines presently has a consensus price target of $402.14, suggesting a potential upside of 8.11%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 3 Strong Buy rating(s) 3.00 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer ONC or TAK?

In the previous week, Takeda Pharmaceutical had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 9 mentions for Takeda Pharmaceutical and 2 mentions for BeOne Medicines. Takeda Pharmaceutical's average media sentiment score of 0.63 beat BeOne Medicines' score of 0.53 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BeOne Medicines (ONC) Competitors

$371.98 -2.49 (-0.66%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$361.88 -10.11 (-2.72%)

As of 08/24/2026 05:33 PM Eastern

Compare

ONC vs. PFE, BMY, SNY, GSK, and TAK

Should you buy BeOne Medicines stock or one of its competitors? BeOne Medicines's main competitors and comparable companies include Pfizer (PFE), Bristol Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), and Takeda Pharmaceutical (TAK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BeOne Medicines compare to Pfizer?

Pfizer (NYSE:PFE) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

BeOne Medicines has a net margin of 10.70% compared to Pfizer's net margin of 6.80%. Pfizer's return on equity of 19.63% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
BeOne Medicines	10.70%	14.23%	7.82%

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 0.6% of Pfizer shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Pfizer has higher revenue and earnings than BeOne Medicines. Pfizer is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.55	$7.77B	$0.76	36.80
BeOne Medicines	$5.34B	7.64	$286.93M	$5.68	65.49

In the previous week, Pfizer had 92 more articles in the media than BeOne Medicines. MarketBeat recorded 94 mentions for Pfizer and 2 mentions for BeOne Medicines. Pfizer's average media sentiment score of 0.94 beat BeOne Medicines' score of 0.53 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	54 Very Positive mention(s)	12 Positive mention(s)	15 Neutral mention(s)	7 Negative mention(s)	5 Very Negative mention(s)	Positive
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer currently has a consensus target price of $28.28, indicating a potential upside of 1.11%. BeOne Medicines has a consensus target price of $402.14, indicating a potential upside of 8.11%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

Pfizer has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Summary

BeOne Medicines beats Pfizer on 10 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Bristol Myers Squibb?

BeOne Medicines (NASDAQ:ONC) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Bristol Myers Squibb has higher revenue and earnings than BeOne Medicines. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.64	$286.93M	$5.68	65.49
Bristol Myers Squibb	$49.19B	2.79	$7.05B	$4.54	14.82

In the previous week, Bristol Myers Squibb had 73 more articles in the media than BeOne Medicines. MarketBeat recorded 75 mentions for Bristol Myers Squibb and 2 mentions for BeOne Medicines. Bristol Myers Squibb's average media sentiment score of 1.53 beat BeOne Medicines' score of 0.53 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	68 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

BeOne Medicines currently has a consensus target price of $402.14, suggesting a potential upside of 8.11%. Bristol Myers Squibb has a consensus target price of $66.06, suggesting a potential downside of 1.85%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities research analysts plainly believe BeOne Medicines is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Bristol Myers Squibb has a net margin of 18.87% compared to BeOne Medicines' net margin of 10.70%. Bristol Myers Squibb's return on equity of 66.90% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Bristol Myers Squibb	18.87%	66.90%	14.74%

Summary

Bristol Myers Squibb beats BeOne Medicines on 9 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Sanofi?

Sanofi (NASDAQ:SNY) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Sanofi presently has a consensus price target of $49.50, indicating a potential upside of 8.34%. BeOne Medicines has a consensus price target of $402.14, indicating a potential upside of 8.11%. Given Sanofi's higher probable upside, analysts plainly believe Sanofi is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

Sanofi has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

In the previous week, BeOne Medicines had 2 more articles in the media than Sanofi. MarketBeat recorded 2 mentions for BeOne Medicines and 0 mentions for Sanofi. Sanofi's average media sentiment score of 1.02 beat BeOne Medicines' score of 0.53 indicating that Sanofi is being referred to more favorably in the media.

Company	Overall Sentiment
Sanofi	Positive
BeOne Medicines	Positive

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.24	$8.84B	$1.91	23.92
BeOne Medicines	$5.34B	7.64	$286.93M	$5.68	65.49

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BeOne Medicines has a net margin of 10.70% compared to Sanofi's net margin of 8.66%. BeOne Medicines' return on equity of 14.23% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
BeOne Medicines	10.70%	14.23%	7.82%

Summary

BeOne Medicines beats Sanofi on 12 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to GSK?

BeOne Medicines (NASDAQ:ONC) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.64	$286.93M	$5.68	65.49
GSK	$43.07B	2.43	$7.54B	$3.20	16.19

GSK has a net margin of 14.56% compared to BeOne Medicines' net margin of 10.70%. GSK's return on equity of 43.23% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
GSK	14.56%	43.23%	11.60%

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

BeOne Medicines presently has a consensus price target of $402.14, indicating a potential upside of 8.11%. GSK has a consensus price target of $53.00, indicating a potential upside of 2.33%. Given BeOne Medicines' stronger consensus rating and higher probable upside, research analysts plainly believe BeOne Medicines is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10

In the previous week, BeOne Medicines and BeOne Medicines both had 2 articles in the media. GSK's average media sentiment score of 0.55 beat BeOne Medicines' score of 0.53 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BeOne Medicines beats GSK on 9 of the 16 factors compared between the two stocks.

How does BeOne Medicines compare to Takeda Pharmaceutical?

BeOne Medicines (NASDAQ:ONC) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

BeOne Medicines presently has a consensus price target of $402.14, suggesting a potential upside of 8.11%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market.

In the previous week, Takeda Pharmaceutical had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 9 mentions for Takeda Pharmaceutical and 2 mentions for BeOne Medicines. Takeda Pharmaceutical's average media sentiment score of 0.63 beat BeOne Medicines' score of 0.53 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has higher earnings, but lower revenue than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.64	$286.93M	$5.68	65.49
Takeda Pharmaceutical	$28.32B	2.06	-$1.01B	$0.34	53.64

BeOne Medicines has a net margin of 10.70% compared to Takeda Pharmaceutical's net margin of 3.80%. BeOne Medicines' return on equity of 14.23% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

Summary

BeOne Medicines beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

Get BeOne Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONC vs. The Competition

Export

Metric	BeOne Medicines	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$41.11B	$12.54B	$7.36B	$12.81B
Dividend Yield	N/A	2.61%	2.53%	10.78%
P/E Ratio	65.49	780.42	270.56	24.05
Price / Sales	7.64	758.20	639.67	105.69
Price / Cash	95.81	15.47	29.03	36.89
Price / Book	9.35	10.42	11.18	6.40
Net Income	$286.93M	$2.79B	$3.46B	$347.95M
7 Day Performance	0.77%	1.80%	1.73%	1.49%
1 Month Performance	14.14%	4.70%	7.34%	5.15%
1 Year Performance	20.53%	7.66%	26.12%	17.01%

BeOne Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONC BeOne Medicines	3.7633 of 5 stars	$371.98 -0.7%	$402.14 +8.1%	+18.6%	$41.11B	$5.34B	65.49	12,000
PFE Pfizer	3.3584 of 5 stars	$28.07 +1.0%	$28.28 +0.7%	+8.3%	$159.99B	$62.58B	36.93	75,000
BMY Bristol Myers Squibb	4.2066 of 5 stars	$67.29 +2.8%	$66.06 -1.8%	+40.7%	$137.45B	$48.19B	14.82	32,500	Positive News
SNY Sanofi	2.9745 of 5 stars	$45.97 +1.8%	$49.50 +7.7%	-11.0%	$111.45B	$48.92B	24.07	74,846	Positive News
GSK GSK	2.9522 of 5 stars	$52.41 +0.9%	$53.00 +1.1%	+29.0%	$106.01B	$43.07B	16.39	66,841	Dividend Cut

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONC) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeOne Medicines (ONC) Competitors

ONC vs. PFE, BMY, SNY, GSK, and TAK

How does BeOne Medicines compare to Pfizer?

Summary

How does BeOne Medicines compare to Bristol Myers Squibb?

Summary

How does BeOne Medicines compare to Sanofi?

Summary

How does BeOne Medicines compare to GSK?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeOne Medicines (ONC) Competitors

ONC vs. PFE, BMY, SNY, GSK, and TAK

How does BeOne Medicines compare to Pfizer?

Is PFE or ONC more profitable?

Do institutionals and insiders hold more shares of PFE or ONC?

Which has stronger valuation & earnings, PFE or ONC?

Does the media refer more to PFE or ONC?

Do analysts rate PFE or ONC?

Which has more volatility and risk, PFE or ONC?

Summary

How does BeOne Medicines compare to Bristol Myers Squibb?

Which has better valuation & earnings, ONC or BMY?

Does the media favor ONC or BMY?

Which has more risk and volatility, ONC or BMY?

Do analysts prefer ONC or BMY?

Do insiders and institutionals have more ownership in ONC or BMY?

Is ONC or BMY more profitable?

Summary

How does BeOne Medicines compare to Sanofi?

Do analysts rate SNY or ONC?

Which has more risk and volatility, SNY or ONC?

Does the media refer more to SNY or ONC?

Which has preferable valuation and earnings, SNY or ONC?

Do institutionals and insiders believe in SNY or ONC?

Is SNY or ONC more profitable?

Summary

How does BeOne Medicines compare to GSK?

Which has preferable earnings & valuation, ONC or GSK?

Is ONC or GSK more profitable?

Do insiders and institutionals believe in ONC or GSK?

Which has more volatility and risk, ONC or GSK?

Do analysts recommend ONC or GSK?

Does the media favor ONC or GSK?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Do analysts recommend ONC or TAK?

Do insiders & institutionals have more ownership in ONC or TAK?

Which has more volatility & risk, ONC or TAK?

Does the media prefer ONC or TAK?

Which has better valuation & earnings, ONC or TAK?

Is ONC or TAK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools